[精品]肿瘤细胞系转分化为神经元：不罕见但有效？

[精品]肿瘤细胞系转分化为神经元：不罕见但有效？ 抗脊髓散发胶质瘤发生:Notch通路可成为其治疗新靶点, Notch通路参与肿瘤的形成。在不考虑CD133和其他表面标志物的情况下，如果胶质瘤细胞中只有Notch 阳性表达，是否说明肿瘤干细胞的自我更新或有成瘤趋势,虽然关于大脑胶质瘤干细胞的研究很多，但尚 未发现关于复发脊髓星形胶质瘤干细胞的研究。来自中国北京大学第三医院孙建军博士所在课题组于《中 国神经再生研究(英文版)》杂志2015年第2期发表文章，聚焦于Notch通路在含有少量脊髓髓内胶质瘤 细胞的脑移植胶质瘤形成中的作用。他们在实验中分别给予BALB/c裸小鼠大脑注射来源于人复发脊髓星 形胶质瘤CD133阳性和阴性细胞悬液。注射后7-11周，每周进行MRI检测，发现移植CD133阳性胶质 瘤细胞小鼠大脑表面形成移植瘤，移植瘤Notch免疫阳性表达;移植CD133阴性胶质瘤细胞小鼠大脑表 面无移植瘤形成，几乎未见Notch免疫阳性表达。HE和免疫组化染色检测到移植CD133阳性胶质瘤细胞 小鼠大脑凸面形成移植瘤，一些散发的星形胶质瘤细胞形成伪足样结构浸润大脑白质。说明Notch通路在 星形胶质细胞瘤形成中有重要作用，是治疗脊髓星形胶质细胞瘤的新靶点, Article: "Prevention against diffuse spinal cord astrocytoma: can the Notch pathway be a novel treatment target?" by 11233, 4511Jian-jun Sun, Zhen-yu Wang, Ling-song Li, Hai-yan Yu, Yong-sheng Xu, Hai-bo Wu, Yi Luo, Bin Liu, Mei 6781 Department of Neurosurgery, Peking University Third Hospital, Peking University, Zheng, Jin-long Mao, Xiao-hui Lou ( Beijing, China; 2 China Stem Cell Research Center, Peking University Health Science Center, Peking University, Beijing, China; 3 Clinical Stem Cell Center, Peking University Third Hospital, Peking University, Beijing, China; 4 Clinical Laboratory of Tissue & Cell Research Center, Department of Biotech Treatment, Logistics College of Chinese People’s Armed Police Force, Tianjin, China; 5 Department of Neuroradiology, Peking University Third Hospital, Peking University, Beijing, China; 6 Department of Neurology, Peking University Third Hospital, Peking University, Beijing, China; 7 Neurosurgical Department, Peking Union Medical College Hospital, Beijing, China; 8 Department of Neurosurgery, Rui’an People’s Hospital, Wenzhou Medical University, Wenzhou, Zhejiang Province, China) Sun JJ, Wang ZY, Li LS, Yu HY, Xu YS, Wu HB, Luo Y, Liu B, Zheng M, Mao JL, Lou XH (2015) Prevention against diffuse spinal cord astrocytoma: can the Notch pathway be a novel treatment target? Neural Regen Res 10(2):244-251. 欲获更多资讯: Neural Regen Res Is the Notch pathway a novel target for preventing diffuse spinal cord astrocytoma? The Notch pathway is involved in the formation of a tumor. A new hypothesis was proposed by some scientists that glioma cells would only become cancer stem cells if Notch is expressed, leading to sustained self-renewal and potent tumorigenicity, regardless of the expression of CD133 or other markers. There are many studies reporting on brain glioma cells, but few studies are about recurred spinal cord astrocytoma. Dr. Jian-jun Sun, Peking University Third Hospital, China and his colleagues reported a study in Neural Regeneration Research (Vol. 10, No. 2, 2015). In this study, they investigated the key role of the Notch pathway in the development of cerebral xenografts from only a few original spinal cord intramedullary +astrocytoma cells. In the experiments, the right parietal lobe of BALB/c nude mice were injected CD133 ?and CD133 cell suspensions prepared using human recurrent diffuse spinal cord astrocytoma tissue. At 7–11 weeks, magnetic resonance imaging was performed weekly. Xenografts were observed on the surfaces of the +brains of mice receiving the CD133 cell suspension, and Notch-immunopositive expression was observed in the xenografts. By contrast, no xenografts appeared in the identical position on the surfaces of the brains of ?mice receiving the CD133 cell suspension, and Notch-immunopositive expression was hardly detected either. Hematoxylin-eosin and immunohistochemical staining revealed xenografts on the convex surfaces of the brains of mice that underwent CD133+ astrocytoma transplantation. Some sporadic astroglioma cells showed pseudopodium-like structures, which extended into the cerebral white matter. These findings suggest that the Notch pathway plays an important role in the formation of astrocytomas, and can be considered a novel treatment target for diffuse spinal cord astrocytoma. Article: "Prevention against diffuse spinal cord astrocytoma: can the Notch pathway be a novel treatment target?" by 11233, 4511Jian-jun Sun, Zhen-yu Wang, Ling-song Li, Hai-yan Yu, Yong-sheng Xu, Hai-bo Wu, Yi Luo, Bin Liu, Mei 6781 Department of Neurosurgery, Peking University Third Hospital, Peking University, Zheng, Jin-long Mao, Xiao-hui Lou ( Beijing, China; 2 China Stem Cell Research Center, Peking University Health Science Center, Peking University, Beijing, China; 3 Clinical Stem Cell Center, Peking University Third Hospital, Peking University, Beijing, China; 4 Clinical Laboratory of Tissue & Cell Research Center, Department of Biotech Treatment, Logistics College of Chinese People’s Armed Police Force, Tianjin, China; 5 Department of Neuroradiology, Peking University Third Hospital, Peking University, Beijing, China; 6 Department of Neurology, Peking University Third Hospital, Peking University, Beijing, China; 7 Neurosurgical Department, Peking Union Medical College Hospital, Beijing, China; 8 Department of Neurosurgery, Rui’an People’s Hospital, Wenzhou Medical University, Wenzhou, Zhejiang Province, China) Sun JJ, Wang ZY, Li LS, Yu HY, Xu YS, Wu HB, Luo Y, Liu B, Zheng M, Mao JL, Lou XH (2015) Prevention against diffuse spinal cord astrocytoma: can the Notch pathway be a novel treatment target? Neural Regen Res 10(2):244-251.